Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

The New England journal of medicine - 10 Dec 2020

Hussain Maha, Mateo Joaquin, Fizazi Karim, Saad Fred, Shore Neal, Sandhu Shahneen, Chi Kim N, Sartor Oliver, Agarwal Neeraj, Olmos David, Thiery-Vuillemin Antoine, Twardowski Przemyslaw, Roubaud Guilhem, Özgüroğlu Mustafa, Kang Jinyu, Burgents Joseph, Gresty Christopher, Corcoran Claire, Adelman Carrie A, de Bono Johann

Abstract excerpt

BACKGROUND: We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, BRCA1
Share to Phthalazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ataxia Telangiectasia Mutated Proteins

Share to Bridged-Ring Compounds

Share to Cyclin-Dependent Kinases

Share to Piperazines

Share to Prostatic Neoplasms, Castration-Resistant

Share to Taxoids

Source

Identifiers

PMID: 32955174
DOI: 10.1056/NEJMoa2022485

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.PMID 32955174Read ↗

Olaparib for Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 , or ATM Alterations Identified by Testing Circulating Tumor DNASemantic proximity Read ↗

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient SelectionSemantic proximity Read ↗

Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study.Semantic proximity Read ↗

Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial.Semantic proximity Read ↗

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.Semantic proximity Read ↗

A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.Semantic proximity Read ↗

Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate CancerSemantic proximity Read ↗

Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysisSemantic proximity Read ↗

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM MutationsSemantic proximity Read ↗

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.Semantic proximity Read ↗

Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent g-rate method ideal for real-world analyses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.